
LEMAITRE VASCULAR INC
LMATNASDAQTrading Snapshot
- Day Range
- $80.12 β $81.83
- 52-Week Range
- $78.65 β $118.01
- Volume
- $1.79B
- Avg Volume
- $1.83B
- Shares Outstanding
- 22.9M
- Next Earnings
- Oct 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $250M
- Last Q Revenue
- $70M
- P/E Ratio
- 28.6
- P/S Ratio
- 7.2x
- EPS (TTM)
- $2.77
- Dividend Yield
- 1.09%
Why Investors Own LMAT
- βHigh-growth profile β revenue up +20.9% YoY with expanding US Equity exposure.
- βHealthy economics β 71% gross margin and 30% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About LEMAITRE VASCULAR INC
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
LEMAITRE VASCULAR INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift LMAT price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
LEMAITRE VASCULAR INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.